These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30533403)

  • 1. Model for End-Stage Liver Disease and Sodium Velocity Predicts Overall Survival in Nonmetastatic Hepatocellular Carcinoma Patients.
    Tang JY; Ohri N; Kabarriti R; Aparo S; Chuy J; Goel S; Schwartz JM; Kinkhabwala M; Kaubisch A; Guha C
    Can J Gastroenterol Hepatol; 2018; 2018():5681979. PubMed ID: 30533403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey.
    Huo TI; Lin HC; Hsia CY; Huang YH; Wu JC; Chiang JH; Chiou YY; Lui WY; Lee PC; Lee SD
    Dig Liver Dis; 2008 Nov; 40(11):882-9. PubMed ID: 18339595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
    Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MELD-Na > 16 is associated with high peri-procedural and short-term mortality in patients with ruptured hepatocellular carcinoma treated with emergent transarterial embolization.
    Jundt MC; Owen RL; Thompson SM; Fleming CJ; Stockland AH; Andrews JC
    Abdom Radiol (NY); 2022 Jan; 47(1):416-422. PubMed ID: 34633495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma.
    Hong YF; Chen ZH; Ma XK; Li X; Wu DH; Chen J; Dong M; Wei L; Wang TT; Ruan DY; Lin ZX; Wen JY; Lin Q; Jia CC; Wu XY
    Tumour Biol; 2016 Apr; 37(4):5265-73. PubMed ID: 26561464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model for end-stage liver disease and model for end-stage liver disease-Na scores predict both before-listing and wait-list mortality.
    Yamashiki N; Sugawara Y; Tamura S; Kaneko J; Nojiri K; Aoki T; Sakamoto Y; Hasegawa K; Koike K; Kokudo N
    Transplant Proc; 2012 Mar; 44(2):389-92. PubMed ID: 22410024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
    Kim JH; Kim JH; Choi JH; Kim CH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    Scand J Gastroenterol; 2009; 44(3):346-57. PubMed ID: 18991165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S; Rhim H; Kim YS; Kang TW; Song KD
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems.
    Huo TI; Hsia CY; Huang YH; Lin HC; Lee PC; Lui WY; Chiang JH; Chiou YY; Loong CC; Lee SD
    J Clin Gastroenterol; 2009 Sep; 43(8):773-81. PubMed ID: 19262404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum sodium and hydration status predict transplant-free survival independent of MELD score in patients with cirrhosis.
    Mathur S; Gane EJ; McCall JL; Plank LD
    J Gastroenterol Hepatol; 2008 Feb; 23(2):239-43. PubMed ID: 17489965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices.
    Amitrano L; Guardascione MA; Bennato R; Manguso F; Balzano A
    J Hepatol; 2005 Jun; 42(6):820-5. PubMed ID: 15885352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
    Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
    Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Region 11 MELD Na exception prospective study.
    Fisher RA; Heuman DM; Harper AM; Behnke MK; Smith AD; Russo MW; Zacks S; McGillicuddy JW; Eason J; Porayko MK; Northup P; Marvin MR; Hundley J; Nair S
    Ann Hepatol; 2012; 11(1):62-7. PubMed ID: 22166562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
    Berry K; Ioannou GN
    Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma.
    Hsu HY; Yu MC; Lee CW; Tsai HI; Sung CM; Chen CW; Huang SW; Lin CY; Jeng WJ; Lee WC; Chen MF
    BMC Cancer; 2017 Nov; 17(1):742. PubMed ID: 29121890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretransplant predictors of early mortality in adult recipients of liver transplantation in the MELD-Na Era.
    Pozo-Laderas JC; Rodríguez-Perálvarez M; Muñoz-Villanueva MC; Rivera-Espinar F; Durban-García I; Muñoz-Trujillo J; Robles-Arista JC; Briceño-Delgado J
    Med Intensiva (Engl Ed); 2019; 43(5):261-269. PubMed ID: 29735173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.
    Brown DB; Fundakowski CE; Lisker-Melman M; Crippin JS; Pilgram TK; Chapman W; Darcy MD
    J Vasc Interv Radiol; 2004 Nov; 15(11):1209-18. PubMed ID: 15525739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma.
    Limquiaco JL; Wong GL; Wong VW; Lai PB; Chan HL
    J Gastroenterol Hepatol; 2009 Jan; 24(1):63-9. PubMed ID: 19054256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft.
    Yi NJ; Suh KS; Lee HW; Shin WY; Kim J; Kim W; Kim YJ; Yoon JH; Lee HS; Lee KU
    Liver Transpl; 2009 May; 15(5):496-503. PubMed ID: 19399732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.